Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis
Treating KRAS-mutant lung adenocarcinoma (LUAD) remains a major challenge in cancer treatment given the difficulties associated with directly inhibiting the KRAS oncoprotein. One approach to addressing this challenge is to define mutations that frequently co-occur with those in KRAS, which themselve...
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Other Authors: | , , |
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group,
2018-06-22T19:12:01Z.
|
Subjects: | |
Online Access: | Get fulltext |